Contacts

MedinCell provides additional information regarding the new drug application for mdc-IRM

April 20, 2022

 As announced, Teva recently* received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the New Drug Application (NDA) for TV-46000/mdc-IRM. 

Christophe Douat, CEO of MedinCell, said “We fully trust that our partner, Teva, will remedy this quickly given the positive results of the Phase 3 studies. Teva remains confident in MedinCell’s technology for the development of extended-release injectable products.” 

A Complete Response Letter is issued when the FDA determines that it cannot approve the application in its current form. Where possible, the FDA will recommend corrective actions that the applicant might take to place the application in condition for approval. 

Dr. Richard Malamut, President of MedinCell’s Medical Advisory Board, said “CRLs are a common part of the FDA regulatory process and resubmission after addressing identified deficiencies frequently leads to approval”. 

Teva remains committed to the development of extended-release injectable risperidone and other products based on MedinCell’s technology. 

*Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
https://www.medincell.com/en/2022/04/19/teva-and-medincell-receive-complete-response-letter-for-tv-46000-mdc-irm/

Session en français

Rendez-vous le mardi 14 juin à 18h30 (CEST) pour une vidéoconférence dédiée aux résultas annuel 2021-2022

English session

On Tuesday 14, June at 7.30 pm (CEST) participate in our videoconference dedicated to our Financial year 2021-2022 results

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.